LivingGLP1
Study S001768

Efficacy of Once-Weekly Exenatide Long-Acting Release and Once-Daily Insulin Glargine in Patients With Type 2 Diabetes Treated With Metformin Alone or in Combination With Sulfonylurea

Included trial: extracted dataClinicalTrials.gov record

Registration

Registration
NCT00641056
Study type
INTERVENTIONAL
Allocation
RANDOMIZED
Phase
PHASE3
Masking
NONE
Status
COMPLETED
Enrollment
467
Start
2008-04
Primary completion
2009-05
Lead sponsor
AstraZeneca
Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG:Exenatide Once Weekly; DRUG:Insulin Glargine
Results posted
TRUE

Registered primary outcomes

  • Change in HbA1c From Baseline to Week 26 [Baseline, Week 26]

Linked records (10)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0013562Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease.
Guja C, Diabetes therapy : research, treatment and education of diabetes and related disorders
2020Other trialPMID 32306296DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:32306296
R0048863Anhaltende Blutzuckerkontrolle unter wöchentlichem Depot-Exenatide versus Insulin glargin: Assoziation mit Basischarakteristika und frühem Therapieansprechen
Marcel Trautmann, Diabetologie und Stoffwechsel
2015OtherDOIcites ClinicalTrials.gov:NCT00641056
R0022390Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial.
Diamant M, The lancet. Diabetes & endocrinology
2014Randomized trialPMID 24731672DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:24731672
R0019490Efficacy, safety, and tolerability of exenatide once weekly in patients with type 2 diabetes mellitus: an integrated analysis of the DURATION trials.
Grimm M, Postgraduate medicine
2013Randomized trialPMID 23748506DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:23748506
R0024240Treatment of patients with type 2 diabetes with exenatide once weekly versus oral glucose-lowering medications or insulin glargine: achievement of glycemic and cardiovascular goals.
Meloni AR, Cardiovascular diabetology
2013Randomized trialPMID 23522121DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:23522121
R0049258Once-Weekly Exenatide Allows Sustained HbA1C Control
Brian D. Hoyle, MD Conference Express
2013Randomized trialDOIcites ClinicalTrials.gov:NCT00641056
R0052015DURATION-3 Trial Results
Brian D. Hoyle, MD Conference Express
2013Other trialDOIcites ClinicalTrials.gov:NCT00641056
R0026474Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment.
Fineman MS, Diabetes, obesity & metabolism
2012OtherPMID 22236356DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:22236356
R0027747Safety and efficacy of once-weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes over 84 weeks.
Diamant M, Diabetes care
2012Randomized trialPMID 22357185DOIregistry reference RESULT:22357185
R0027273Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial.
Diamant M, Lancet (London, England)
2010Randomized trialPMID 20609969DOIcites ClinicalTrials.gov:NCT00641056; registry reference DERIVED:20609969